Research Summary

I am a physician-scientist whose research program focuses on hematopoietic growth control, genetic mechanisms underlying leukemogenesis, aberrant Ras signaling in human developmental disorders and cancer, mouse cancer modeling, and molecular therapeutics. I served as Director of the UCSF Medical Scientist Training Program (MSTP) from 2006-2012. I have been a research mentor for medical students, graduate students, and post-doctoral scholars, including six post-doctoral scholars who received “K” series awards from the NCI.

Research Funding

  • September 15, 2024 - September 14, 2026 - RAF Dimer Inhibitor Treatment in Pediatric Acute Myeloid Leukemia , Principal Investigator . Sponsor: Alex’s Lemonade Stand Foundation, Sponsor Award ID: Innovation Award
  • September 1, 2015 - August 31, 2026 - Developmental and HyperActive Ras Tumor SPORE , Multiple Principal Investigator . Sponsor: NIH, Sponsor Award ID: U54CA196519
  • April 1, 2015 - March 31, 2026 - Selectively Targeting Oncogenic NRAS in Cancer , Principal Investigtor . Sponsor: NIH, Sponsor Award ID: R01CA193994

Education

Williams College, Williamstown, MA, A.B., 1976, Biology, Liberal Arts
Cornell University, New York, NY, M.D., 1979, Medicine
University of Texas Southwestern, Dallas, TX, Resident, 1982, Pediatrics
University of California, San Francisco (UCSF), Postdoctoral, 1988, Hematology/Oncology

Honors & Awards

  • 1992
    Winner, Navy Academic Medicine Research Competition
  • 1993
    Nycomed Research Award of the International Society for Pediatric Oncology (SIOP)
  • 1994
    Ross Outstanding Young Investigator Award, Western Society for Pediatric Research
  • 1998
    American Academy of Pediatrics Award for Excellence in Pediatric Research
  • 2000
    Roma and Marvin Auerback Distinguished Professor of Pediatric Molecular Oncology, UCSF
  • 2004
    Samuel Rosenthal Prize for Excellence in Academic Pediatrics
  • 2006
    National Cancer Institute MERIT Award
  • 2010
    American Association of Physicians
  • 2010
    American Cancer Society Research Professorship
  • 2016
    Team Science Research Award, Children's Tumor Foundation
  • 2019
    Society of Memorial Sloan Kettering Research Prize
  • 2020
    UCSF Faculty Research Lecture in Basic Sciences

Selected Publications

  1. Moore JP, Waldmann V, Bessière F, Babouri N, Cohen MI, O'Leary ET, Patel NS, Nazer B, Tan W, Fish FA, Dalal AS, Mariucci E, Tan RB, Lloyd MS, McLeod CJ, Anderson CC, Kanter RJ, Johnson BV, Wang B, Chang PM, Newlon CA, Su J, Shannon KM, Bradfield JS, Shivkumar K, Aboulhosn JA, Khairy P. Age-Related Ventricular Tachycardia Substrate Characteristics for Repaired Tetralogy of Fallot Before Transcatheter Pulmonary Valve Placement. JACC Clin Electrophysiol. 2025 Mar; 11(3):551-562.  View on PubMed
  2. Wong JC, Weinfurtner KM, Westover T, Kim J, Lebish EJ, Del Pilar Alzamora M, Huang BJ, Walsh M, Abdelhamed S, Ma J, Klco JM, Shannon K. 5G2 mutant mice model loss of a commonly deleted segment of chromosome 7q22 in myeloid malignancies. Leukemia. 2024 May; 38(5):1182-1186.  View on PubMed
  3. Chen PY, Huang BJ, Harris M, Boone C, Wang W, Carias H, Mesiona B, Mavrici D, Kohler AC, Bollag G, Zhang C, Zhang Y, Shannon K. Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation. JCI Insight. 2023 09 08; 8(17).  View on PubMed
  4. Levinson AL, Tjoa K, Huang B, Meyer LK, Kim MO, Brady SW, Zhang J, Shannon K, Wandler AM. Opposing effects of KDM6A and JDP2 on glucocorticoid sensitivity in T-ALL. Blood Adv. 2023 07 25; 7(14):3479-3484.  View on PubMed
  5. Blakeley JO, Shannon K. Precision Oncology for Papillary Craniopharyngioma. N Engl J Med. 2023 Jul 13; 389(2):179-181.  View on PubMed
  6. Shannon K. The CCDI Comes Out of the Starting Block. J Clin Oncol. 2023 08 20; 41(24):3973-3975.  View on PubMed
  7. Huang BJ, Shannon K. NFIA-ETO2, TP53, and erythroid leukemogenesis. Blood. 2023 05 04; 141(18):2168-2170.  View on PubMed
  8. Popescu B, Shannon K. Sidestepping SHP2 inhibition. J Exp Med. 2023 05 01; 220(5).  View on PubMed
  9. de Blank PMK, Gross AM, Akshintala S, Blakeley JO, Bollag G, Cannon A, Dombi E, Fangusaro J, Gelb BD, Hargrave D, Kim A, Klesse LJ, Loh M, Martin S, Moertel C, Packer R, Payne JM, Rauen KA, Rios JJ, Robison N, Schorry EK, Shannon K, Stevenson DA, Stieglitz E, Ullrich NJ, Walsh KS, Weiss BD, Wolters PL, Yohay K, Yohe ME, Widemann BC, Fisher MJ. MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus. Neuro Oncol. 2022 11 02; 24(11):1845-1856.  View on PubMed
  10. Carnevale J, Shifrut E, Kale N, Nyberg WA, Blaeschke F, Chen YY, Li Z, Bapat SP, Diolaiti ME, O'Leary P, Vedova S, Belk J, Daniel B, Roth TL, Bachl S, Anido AA, Prinzing B, Ibañez-Vega J, Lange S, Haydar D, Luetke-Eversloh M, Born-Bony M, Hegde B, Kogan S, Feuchtinger T, Okada H, Satpathy AT, Shannon K, Gottschalk S, Eyquem J, Krenciute G, Ashworth A, Marson A. RASA2 ablation in T cells boosts antigen sensitivity and long-term function. Nature. 2022 09; 609(7925):174-182.  View on PubMed
  11. Suciu RM, Luvaga IK, Hazeen A, Weerasooriya C, Richardson SK, Firestone AJ, Shannon K, Howell AR, Cravatt BF. Chemical proteomic analysis of palmostatin beta-lactone analogs that affect N-Ras palmitoylation. Bioorg Med Chem Lett. 2021 12 01; 53:128414.  View on PubMed
  12. Remsberg JR, Suciu RM, Zambetti NA, Hanigan TW, Firestone AJ, Inguva A, Long A, Ngo N, Lum KM, Henry CL, Richardson SK, Predovic M, Huang B, Dix MM, Howell AR, Niphakis MJ, Shannon K, Cravatt BF. ABHD17 regulation of plasma membrane palmitoylation and N-Ras-dependent cancer growth. Nat Chem Biol. 2021 08; 17(8):856-864.  View on PubMed
  13. Wong JC, Perez-Mancera PA, Huang TQ, Kim J, Grego-Bessa J, Del Pilar Alzamora M, Kogan SC, Sharir A, Keefe SH, Morales CE, Schanze D, Castel P, Hirose K, Huang GN, Zenker M, Sheppard D, Klein OD, Tuveson DA, Braun BS, Shannon K. KrasP34R and KrasT58I mutations induce distinct RASopathy phenotypes in mice. JCI Insight. 2020 11 05; 5(21).  View on PubMed
  14. Pucciarelli D, Angus SP, Huang B, Zhang C, Nakaoka HJ, Krishnamurthi G, Bandyopadhyay S, Clapp DW, Shannon K, Johnson GL, Nakamura JL. Nf1-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK. Mol Cancer Ther. 2020 11; 19(11):2382-2395.  View on PubMed
  15. Shannon K, Link DC. Soil and Seed: Coconspirators in Therapy-Induced Myeloid Neoplasms. Blood Cancer Discov. 2020 07; 1(1):10-12.  View on PubMed
  16. Zambetti NA, Firestone AJ, Remsberg JR, Huang BJ, Wong JC, Long AM, Predovic M, Suciu RM, Inguva A, Kogan SC, Haigis KM, Cravatt BF, Shannon K. Genetic disruption of N-RasG12D palmitoylation perturbs hematopoiesis and prevents myeloid transformation in mice. Blood. 2020 05 14; 135(20):1772-1782.  View on PubMed
  17. Wandler AM, Huang BJ, Craig JW, Hayes K, Yan H, Meyer LK, Scacchetti A, Monsalve G, Dail M, Li Q, Wong JC, Weinberg O, Hasserjian RP, Kogan SC, Jonsson P, Yamamoto K, Sampath D, Nakitandwe J, Downing JR, Zhang J, Aster JC, Taylor BS, Shannon K. Loss of glucocorticoid receptor expression mediates in vivo dexamethasone resistance in T-cell acute lymphoblastic leukemia. Leukemia. 2020 08; 34(8):2025-2037.  View on PubMed
  18. Meyer LK, Huang BJ, Delgado-Martin C, Roy RP, Hechmer A, Wandler AM, Vincent TL, Fortina P, Olshen AB, Wood BL, Horton TM, Shannon KM, Teachey DT, Hermiston ML. Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes. J Clin Invest. 2020 02 03; 130(2):863-876.  View on PubMed
  19. Bhatia S, Chen Y, Wong FL, Hageman L, Smith K, Korf B, Cannon A, Leidy DJ, Paz A, Andress JE, Friedman GK, Metrock K, Neglia JP, Arnold M, Turcotte LM, de Blank P, Leisenring W, Armstrong GT, Robison LL, Clapp DW, Shannon K, Nakamura JL, Fisher MJ. Subsequent Neoplasms After a Primary Tumor in Individuals With Neurofibromatosis Type 1. J Clin Oncol. 2019 11 10; 37(32):3050-3058.  View on PubMed
  20. Meyer LK, Delgado-Martin C, Maude SL, Shannon KM, Teachey DT, Hermiston ML. CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition. PLoS One. 2019; 14(7):e0220026.  View on PubMed

Go to UCSF Profiles, powered by CTSI